Navellier & Associates Inc boosted its stake in Pfizer, Inc. (NYSE:PFE) by 7.3% during the first quarter, according to its most recent filing with the SEC. The firm owned 10,506 shares of the biopharmaceutical company’s stock after buying an additional 711 shares during the period. Navellier & Associates Inc’s holdings in Pfizer were worth $359,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also recently modified their holdings of the company. Asset Planning Services Ltd. boosted its position in shares of Pfizer by 4.9% in the first quarter. Asset Planning Services Ltd. now owns 2,961 shares of the biopharmaceutical company’s stock valued at $101,000 after buying an additional 137 shares in the last quarter. Orrstown Financial Services Inc. boosted its position in shares of Pfizer by 23.0% in the first quarter. Orrstown Financial Services Inc. now owns 3,275 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 612 shares in the last quarter. Fusion Family Wealth LLC purchased a new position in shares of Pfizer during the fourth quarter valued at about $109,000. Cable Hill Partners LLC boosted its position in shares of Pfizer by 6.0% in the first quarter. Cable Hill Partners LLC now owns 4,664 shares of the biopharmaceutical company’s stock valued at $160,000 after buying an additional 265 shares in the last quarter. Finally, D Orazio & Associates Inc. boosted its position in shares of Pfizer by 0.5% in the fourth quarter. D Orazio & Associates Inc. now owns 5,223 shares of the biopharmaceutical company’s stock valued at $170,000 after buying an additional 28 shares in the last quarter. Hedge funds and other institutional investors own 69.95% of the company’s stock.
Pfizer, Inc. (NYSE PFE) opened at 33.25 on Tuesday. The company has a market capitalization of $198.43 billion, a P/E ratio of 27.99 and a beta of 1.01. The firm has a 50-day moving average price of $32.80 and a 200 day moving average price of $33.17. Pfizer, Inc. has a 1-year low of $29.83 and a 1-year high of $37.39.
Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, May 2nd. The biopharmaceutical company reported $0.69 EPS for the quarter, beating the consensus estimate of $0.67 by $0.02. Pfizer had a return on equity of 23.68% and a net margin of 13.76%. The company had revenue of $12.78 billion for the quarter, compared to analyst estimates of $13.09 billion. During the same period last year, the company earned $0.67 earnings per share. Pfizer’s quarterly revenue was down 1.7% compared to the same quarter last year. On average, equities analysts predict that Pfizer, Inc. will post $2.55 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 1st. Shareholders of record on Friday, August 4th will be issued a $0.32 dividend. This represents a $1.28 annualized dividend and a yield of 3.85%. The ex-dividend date of this dividend is Wednesday, August 2nd. Pfizer’s payout ratio is currently 108.48%.
ILLEGAL ACTIVITY NOTICE: This article was reported by Stock Observer and is the sole property of of Stock Observer. If you are accessing this article on another publication, it was illegally copied and reposted in violation of United States & international copyright & trademark laws. The original version of this article can be read at https://www.thestockobserver.com/2017/07/18/navellier-associates-inc-has-359000-stake-in-pfizer-inc-nysepfe-updated.html.
Several analysts recently weighed in on the stock. Jefferies Group LLC reiterated a “hold” rating and issued a $35.00 price target (up previously from $34.00) on shares of Pfizer in a report on Friday. Cowen and Company set a $43.00 price target on shares of Pfizer and gave the company a “buy” rating in a report on Monday, July 10th. Sanford C. Bernstein set a $39.00 price target on shares of Pfizer and gave the company a “buy” rating in a report on Monday. BidaskClub cut shares of Pfizer from a “sell” rating to a “strong sell” rating in a report on Thursday, July 13th. Finally, Zacks Investment Research upgraded shares of Pfizer from a “sell” rating to a “hold” rating in a report on Friday. Two equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and eleven have issued a buy rating to the company’s stock. Pfizer has a consensus rating of “Hold” and a consensus target price of $37.78.
Pfizer Company Profile
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.